高危前列腺癌中溶骨性或混合性骨转移并非少见
高危组成骨性骨转移(8.7% vs 0.3%)、溶骨性或混合性骨转移(3.6% vs 0.2%)、淋巴结转移(14.4% vs 0.3%)及肺转移(2.5% vs 0%)频率均显著高于中低危组(均p<0.0001)。结论提示高危前列腺癌患者出现溶骨性或混合性骨转移并不少见,应纳入鉴别诊断。
要点
- 高危前列腺癌(GS≥8)患者溶骨性或混合性骨转移发生率为3.6%,并非罕见。
- 高危组淋巴结转移(14.4%)和肺转移(2.5%)频率也显著高于中低危组。
- 阅片遇溶骨性或混合性骨转移时,应将高危前列腺癌纳入鉴别诊断。
关键影像表现/征象
- 高危组成骨性骨转移47/527(8.7%),中低危组3/973(0.3%)。
- 高危组溶骨性或混合性骨转移19/527(3.6%),中低危组2/973(0.2%)。
- 高危组淋巴结转移76/527(14.4%),中低危组3/973(0.3%)。
- 高危组肺转移13/527(2.5%),中低危组0%。
诊断标准与关键数值
- 骨转移类型按CT表现分为成骨性、溶骨性或混合性,由两名放射科医生评估。
- 高危组定义为Gleason评分≥8,中低危组定义为Gleason评分≤7。
- 高危组与中低危组各转移频率差异均p<0.0001。
临床应用与阅片要点
- 高危前列腺癌患者出现溶骨性或混合性骨转移并不少见,阅片时不应因前列腺癌而排除此类转移。
- 高危组淋巴结和肺转移频率也更高,报告时应同时关注淋巴结及肺部情况。
- 结合Gleason评分和PSA水平,对高危患者骨病变的定性诊断保持警惕。
局限性
- 本研究为回顾性设计。
- 原文未报告多中心或单中心信息。
- 原文未报告CT设备或扫描参数细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Osteolytic or mixed bone metastases (BMs) are considered rare in prostate cancer (PCa). However, we hypothesized that they are not uncommon in high-risk PCa. This study aimed to compare the clinical and CT imaging characteristics of PCa by focusing on BMs among patients with Gleason score (GS) ≥ 8 (high-risk group) and those with GS ≤ 7 (intermediate-low-risk group).
METHODS: Between 2014 and 2021, patients with pathologically proven PCa and no history of other malignancies were included. Clinical findings including age and prostate-specific antigen (PSA) were collected. CT imaging findings, including the types of BM and other metastases, were evaluated by two radiologists. The clinical and CT imaging findings were compared between the high- and intermediate-low-risk groups.
RESULTS: Patients were classified into high-risk (n = 527) and intermediate-low-risk (n = 973) groups. Age at diagnosis (median: 71 [44-91] vs 69 [35-86] years, p < 0.0001), PSA (8.7 [0.01-15314.5] vs 5.8 [0.01-163.2] ng/mL, p < 0.0001), frequencies of BMs (osteoblastic: 47/527 [8.7%] vs 3/973 [0.3%]), osteolytic or mixed BM (19/527 [3.6%] vs 2/973 [0.2%]), lymph node metastases (76/527 [14.4%] vs 3/973 [0.3%]), and lung metastases (13/527 [2.5%] vs 0%) were significantly higher in the high-risk group than in the intermediate-low-risk group (all p < 0.0001).
CONCLUSIONS: Age, PSA, and the frequencies of osteolytic or mixed BMs were significantly higher in the high-risk group than in the intermediate-low-risk group. This study highlights the importance of high-risk PCa in the differential diagnoses of osteolytic or mixed BMs.
引用
- Kurokawa, Kato, Koyama, et al. Osteolytic or mixed bone metastasis is not uncommon in patients with high-risk prostate cancer. Eur J Radiol. 2022. PMID: 36356462. doi:10.1016/j.ejrad.2022.110595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。